Equilar has released a new report Director Pay Trends, which contains several stunning figures pertaining to board compensation -- such as Regeneron Pharmaceuticals paying its board a total of $18.5M in compensation in 2015. It is noteworthy that the three boards at the top of the list are classified (directors only face re-election every few years as opposed to annually). Thankfully, for shareholders, the number of classified boards in the S&P 500 has dropped to 10.4% (down from 27.9% in 2012). Read the Equilar Report HERE